Skip to main content
Premium Trial:

Request an Annual Quote

Good News for Cancer Patients (the Ones in Boston, Anyway)

This article from the Boston Globe reports that Massachusetts General Hospital will begin to routinely perform genetic screens on "nearly all new patients' tumors, a novel strategy designed to customize treatment." Oncologists will be looking at 110 genetic variants on 13 cancer genes in these patients to help determine the best course of treatment. "Mass. General's decision to make gene testing standard in cancer treatment - it's believed to be the first hospital in the nation to do so - represents a major step in delivering personalized medicine to the masses," the article says.

Over at Omics! Omics!, Keith Robison reacts to the news, agreeing with cancer researchers quoted in the story who say that the clinical outcome of this new program is unclear. Still, Robison calls it "an exciting push forward into personalized medicine" and says that the main benefit may be the database the hospital will assemble from all this. "MGH is also presumably planning to screen patients on both initial diagnosis and after relapses, so an increasingly rich database of mutations appearing during cancer progression will emerge," he writes.

Filed under

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.